OTCMONWRF
Market cap179mUSD
Dec 23, Last price
5.95USD
1D
15.53%
IPO
-6.30%
Name
ONWARD Medical NV
Chart & Performance
P/E
—
P/S
324.56
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
7.70%
Rev. gr., 5y
2.34%
Revenues
532k
-75.23%
Net income
-36m
L+10.40%
CFO
-32m
L+20.93%
Profile
Onward Medical N.V., a medical technology company, focuses on developing therapies for spinal cord injuries in the Netherlands and internationally. The company engages in developing ARCEX, an external non-invasive platform that consists of a wearable stimulator and wireless programmer, which restores or enhances physical movement of hand and arm function to people with spinal cord therapy; and ARCIM, an implantable platform, which consists of an implantable pulse generator and lead that is placed near the spinal cord that enables long-paralyzed people to stand and walk again with little or no assistance. It also engages in developing Up-LIFT Trial to evaluate the safety and effectiveness of ARCEX Therapy in restoring strength and function of upper extremities in people with spinal cord injury. Onward Medical N.V. was founded in 2014 and is headquartered in Eindhoven, Netherlands.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||
Revenues | 532 -75.23% | 2,148 53.54% | 1,399 74.88% | ||||
Cost of revenue | 43,461 | 37,848 | 19,736 | ||||
Unusual Expense (Income) | |||||||
NOPBT | (42,929) | (35,700) | (18,337) | ||||
NOPBT Margin | |||||||
Operating Taxes | 107 | (766) | 69 | ||||
Tax Rate | |||||||
NOPAT | (43,036) | (34,934) | (18,406) | ||||
Net income | (36,181) 10.40% | (32,772) -4.49% | (34,314) 71.45% | ||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | 80,106 | ||||||
BB yield | |||||||
| Debt | |||||||
Debt current | 568 | 427 | 473 | ||||
Long-term debt | 17,925 | 15,671 | 15,406 | ||||
Deferred revenue | 1,387 | ||||||
Other long-term liabilities | 2,081 | 1,121 | 1,000 | ||||
Net debt | (11,275) | (57,916) | (73,564) | ||||
| Cash flow | |||||||
Cash from operating activities | (32,270) | (26,685) | (19,874) | ||||
CAPEX | (422) | (417) | (2,324) | ||||
Cash from investing activities | 19,578 | (20,417) | (2,324) | ||||
Cash from financing activities | 813 | (557) | 105,361 | ||||
FCF | (43,032) | (34,650) | (20,389) | ||||
| Balance | |||||||
Cash | 29,768 | 61,760 | 89,443 | ||||
Long term investments | 12,254 | ||||||
Excess cash | 29,741 | 73,907 | 89,373 | ||||
Stockholders' equity | (137,318) | (102,618) | (72,352) | ||||
Invested Capital | 174,204 | 170,062 | 169,879 | ||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | 30,184 | 30,184 | 30,184 | ||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | (42,203) | (34,965) | (18,008) | ||||
EV/EBITDA | |||||||
Interest | 600 | 1,515 | 5,597 | ||||
Interest/NOPBT | |||||||